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History of cancer theory
Patients with any metastatic or recurrent cancers were 
considered incurable and were not expected to survive for a 
long-term. Samuel Hellman proposed a new theory in 1994 
at the Karnofsky Memorial Lecture (1). This theory was 
termed the spectrum theory. Until this theory was proposed, 
the systemic disease theory was accepted worldwide 
which indicated that all patients with cancer had potential 
metastases even if they did not have metastatic or recurrent 
cancer. Before the systemic disease theory was proposed by 
Bernard Fisher in 1980, cancer was considered to follow the 
Halsted theory, which was proposed by William Stewart 
Halsted in 1894. The Halsted theory suggested that if left 
untreated, cancer consecutively spreads through regional 
lymph nodes and then by hematogenous dissemination to 
the other organs in the body.
For a long time, there have been many investigations 
and discussions on where the systemic disease theory or 
spectrum theory is more accurate. Nowadays, the spectrum 
theory is well accepted among leading cancer professionals. 
The premise of the spectrum theory lies between the 
Halsted and systemic disease theories. According to his 
hypothesis, cancer is a spectrum of diseases than ranges 
from being a local disease to one metastasizes. 
Indeed, some cancers are both local and systemic, which 
can be described as a “spectrum”. Hellman suggested these 
differences raise the “tumor burden” in this hypothesis. 
Because, breast cancer tends to remain a local disease, 
as far as it is a small tumor. More recently, the concepts 
of oligometastases (2), oligo-recurrence (3-5), and sync-
oligometastases (4) have been reported.
History of the concepts of oligometastases, 
oligo-recurrence and sync-oligometastases
In 1995, Hellman and Weichselbaum proposed the concept 
of “oligometastases” (1). This concept was based on the 
spectrum theory and expands beyond small breast cancer. In 
an editorial published in the Journal of Clinical Oncology, they 
suggested that some patients with cancer having metastases 
could have long-term survival. This was the first description 
of oligometastases and related concepts. Around the same 
time, Niibe trained as a medical intern at the National 
Institute of Radiological Sciences Hospital in Japan. He 
observed the disappearance of para-aortic lymph node 
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metastases with uterine cervical cancer patient, following 
treatment with external radiation therapy (6). Furthermore, 
he reviewed the medical charts of patients the same stage 
of the disease and who were previously treated with 
external radiation therapy alone or combined with systemic 
chemotherapy and found that they had long-term survival 
or were even cured. This experience gave him highly 
interest of cancer patients with metastases or recurrences, 
and he began investigating oligometastases: however, at 
that time, he was not aware of this concept because there 
was no internet or PubMed when he trained as a medial 
intern. After his experience, he wrote the original articles 
about par-aortic lymph node metastases or recurrences in 
patients with uterine cervical cancer (7-9), and in 2006, he 
finally proposed the concept of “oligo-recurrence”. The 
differences between oligometastases and oligo-recurrence 
were previously described in detail with figures (3,4). Briefly 
described here, Niibe et al. defined the concept of oligo-
recurrence as the state in which patients had a controlled 
primary cancerous lesion and 1–5 metastatic or recurrent 
cancerous lesions, and all active cancerous lesions could 
be treated with local therapies, such as surgery, radiation 
therapy, radiofrequency ablation, and others with or without 
systemic therapy. In 2012, Niibe and Chang defined sync-
oligometastases as the state in which patients with cancer 
have active primary cancerous lesions and 1–5 metastatic 
or recurrent cancerous lesions, and all active cancerous 
lesions require local treatment, with or without systemic 
therapy. This classification had very important implications 
in the oligometastases field because the prognosis of these 
patients was different. Patients with oligo-recurrence 
have significantly superior outcomes to those with sync-
oligometastatic patients (5,6,10,11). These studies included 
a nationwide survey of 1,378 oligometastases patients 
published in 2020 (5). Nowadays, oligometastases is a 
generous technical term including oligo-recurrence, sync-
oligometastases, oligoprogression and others.
The important caution was reported here. The concept 
of “metachronous Oligometastases” was proposed firstly by 
Niibe and Chang (4).
Future visions of breast cancer
In  2019,  one of  the  biggest  news concerning of 
oligometastases, COMET-SABR randomized phase 2 
reported the final outcomes (12,13). These outcomes 
suggested that the median overall survival of the control 
group (palliation therapy) was 28 months, which was 
significantly inferior to the 41-month overall survival 
of patient in the SABR group (hazard ratio: 0.57, 95% 
confidence interval: 0.30–1.10, P=0.090) (12). The finding 
of this study phase 2 randomized trial was significant as 
they applied a two-sided α of 0.20 and a power of 80%. 
Of the patients in this randomized phase 2 trial, 18% 
had breast cancer. However, the inclusion criteria of this 
randomized phase 2 study were limited to oligo-recurrence. 
The appropriate description of this study’s technical 
terms of oligometastases should be revised to oligo-
recurrence when citing appropriate articles (3,4,14-17). 
This means that our proposed concept of oligo-recurrence 
and retrospective studies of oligo-recurrence are relevant 
to this randomized phase 2 trial (5,14,15). Thus, we re-
emphasize here that the appropriate technical terms use of 
oligo-recurrence should be the standardized according to 
scientific society rules (15,16).
A prospective study for oligo-recurrence from breast 
cancer was reported in 2019 (18). This prospective study 
indicated that patient with 1–3 bone-only oligo-recurrences 
achieved both a long-term local progression-free survival 
(LPFS) and distant progression-free survival (DPFS). The 
LPFS was 100% at 2 years. The 1- and 2-year DPFS were 
80% (95% CI: 62–100%) and 65% (95% CI: 45–95%), 
respectively. Many retrospective studies suggested that 
bone-only oligo-recurrences achieved longer survival 
rates compared with visceral oligo-recurrence (19-22). 
Although retrospective study, Miyata et al. showed that 
90% of patients with oligo-recurrence in lymph node, 
soft tissue, visceral organ and bone had an objective 
response to salvage mainly conventional radiotherapy 
and the 3-year local control rate was 93% in Japan (22). 
Further stereotactic body radiotherapy (SBRT) for oligo-
recurrence in regional lymph node from breast cancer 
without past irradiation history must be performed more 
proactively. Because, Jingu et al., Yamashita et al. and Niibe 
et al. reported excellent results of esophageal or uterine 
cervical cancer lymph node oligo-recurrence treated by 
radiation therapy (23-25) and many radiation oncologists 
also experienced excellent results of breast lymph node 
oligo-recurrence. Moreover, SBRT are expected better 
outcomes of conventional radiation therapy with local 
control, survival and toxicities (5,26).
Further studies exploring the new age of metastatic 
breast cancer and even other cancers should include 
phase 3 clinical trials. To better understand, the detailed 
mechanisms of oligometastases, oligo-recurrence and sync-
oligometastases, including the abscopal effect should also 
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be required (27-29). In this view point of breast cancer 
oligometastases, there is ongoing research in this field: the 
NRG-BR002 is a randomized phase II/III trial assessing 
the role of SBRT or surgical ablation for oligometastatic 
breast cancer patients (30). The authors expect clinical 
trials should require focus on the appropriate combinations 
of  local  therapy and systemic therapy,  including 
immunoradiotherapy and others.
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